Latest news with #LucasMontarce
Yahoo
26-06-2025
- Business
- Yahoo
5 Revealing Analyst Questions From Eli Lilly's Q1 Earnings Call
Eli Lilly's first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring late-stage assets, weighed on profitability. CEO Dave Ricks noted that the company is facing 'a lot of investor focus right now on tariffs and trade,' while CFO Lucas Montarce cited a '26% increase in marketing, selling and administrative expenses' as Lilly ramped up promotion for new launches. Is now the time to buy LLY? Find out in our full research report (it's free). Revenue: $12.73 billion vs analyst estimates of $12.62 billion (45.2% year-on-year growth, 0.9% beat) Adjusted EPS: $3.34 vs analyst expectations of $3.46 (3.4% miss) Adjusted EBITDA: $4.24 billion vs analyst estimates of $5.05 billion (33.3% margin, 16% miss) The company reconfirmed its revenue guidance for the full year of $59.5 billion at the midpoint Management lowered its full-year Adjusted EPS guidance to $21.53 at the midpoint, a 7.4% decrease Operating Margin: 29%, in line with the same quarter last year Market Capitalization: $711.3 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound's market share and future PBM dynamics. CEO Dave Ricks replied that the affected segment is relatively small and emphasized a continued focus on broadening access rather than engaging in exclusive deals. Geoff Meacham (Citibank) questioned whether orforglipron could be developed for more indications beyond diabetes and obesity. Chief Scientific Officer Dr. Dan Skovronsky said oral convenience opens opportunities in broader indications, including primary care and combination therapies. Chris Schott (JPMorgan) sought clarity on the role of orforglipron in the obesity and diabetes markets relative to injectables. President of Cardiometabolic Health Patrik Jonsson noted that many patients prefer oral medications and that orforglipron could reach new populations with needle aversion. Tim Anderson (Bank of America) probed the likelihood and implications of more PBMs shifting to single-product formularies. Jonsson indicated such arrangements remain rare and that the company will continue to prioritize access over exclusivity. James Shin (Deutsche Bank) asked if the pricing headwind guidance remains intact after recent payer decisions. CFO Lucas Montarce confirmed that mid to high single-digit price headwinds are expected to persist and have been factored into the full-year outlook. In the coming quarters, the StockStory team will monitor (1) results from additional Phase 3 trials of orforglipron and their potential to reshape the diabetes and obesity markets; (2) trends in PBM and payer coverage, particularly any changes in employer opt-in rates or further formulary restrictions; and (3) the pace of manufacturing expansions and supply chain execution to meet rising demand. Progress on new product launches and updates on regulatory submissions will also serve as key markers of business momentum. Eli Lilly currently trades at $793, down from $896.02 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Globe and Mail
04-06-2025
- Business
- Globe and Mail
Eli Lilly's (LLY) CFO to Participate in Goldman Sachs Health Conference
Eli Lilly and Co. (LLY) has announced that its chief financial officer (CFO) will participate in the upcoming Goldman Sachs (GS) Global Health Care Conference. Confident Investing Starts Here: Eli Lilly CFO Lucas Montarce will be featured in a fireside chat at the conference at 8 a.m. on June 10. A live audio webcast will be available on Eli Lilly's investor website, and a replay of the presentation will remain on the site for 90 days after the event. It's not clear what will be discussed during the fireside chat, but there is certainly lots to discuss, from Eli Lilly's ongoing battle with rival Novo Nordisk (NVO) for weight loss drug supremacy, to U.S. President Donald Trump's pledge to lower prescription drug costs for Americans, and looming tariffs on pharmaceutical imports. Leading Conference Goldman Sachs' Global Health Care Conference is an annual event that is now in its 46th year. The event brings together leading experts in the health care space to discuss a number of issues impacting the industry, including medical trends, medication breakthroughs, and investment opportunities. As one of America's leading drug makers, Eli Lilly typically has a large presence at the conference. CFO Lucas Montarce's participation in a fireside chat comes as interest grows in Eli Lilly's development of a pill version of its popular Zepbound weight loss medication, which is working its way through regulatory approvals. Is LLY Stock a Buy? The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 17 Buy, one Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,003.60 implies 33.23% upside from current levels.
Associated Press
02-06-2025
- Business
- Associated Press
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time. A live audio webcast will be available on the 'Webcasts & Presentations' section of Lilly's investor website at A replay of the presentation will be available on this same website for approximately 90 days. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. View original content to download multimedia: SOURCE Eli Lilly and Company
Yahoo
02-06-2025
- Business
- Yahoo
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at A replay of the presentation will be available on this same website for approximately 90 days. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company
Yahoo
15-05-2025
- Business
- Yahoo
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price Pressures
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full year's revenue to be around $59.5 billion, close to analysts' estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts' consensus estimates. Is now the time to buy LLY? Find out in our full research report (it's free). Revenue: $12.73 billion vs analyst estimates of $12.62 billion (45.2% year-on-year growth, 0.9% beat) Adjusted EPS: $3.34 vs analyst expectations of $3.46 (3.4% miss) Adjusted EBITDA: $4.25 billion vs analyst estimates of $5.05 billion (33.4% margin, 15.9% miss) The company reconfirmed its revenue guidance for the full year of $59.5 billion at the midpoint Management lowered its full-year Adjusted EPS guidance to $21.53 at the midpoint, a 7.4% decrease Operating Margin: 29%, in line with the same quarter last year Free Cash Flow Margin: 1.2%, similar to the same quarter last year Market Capitalization: $669.8 billion Eli Lilly's first quarter results were driven by significant revenue growth in its key therapeutic areas, notably diabetes and obesity, supported by strong uptake of products such as Mounjaro and Zepbound. Management highlighted the contribution from new launches, expanded reimbursement for immunology products, and the advancement of late-stage pipeline assets. CEO Dave Ricks emphasized the successful Phase 3 data for orforglipron, positioning it as an oral alternative to injectable GLP-1 therapies for chronic diseases. Looking forward, Lilly reconfirmed its annual revenue outlook but lowered its non-GAAP earnings forecast due to ongoing investments and anticipated pricing headwinds. CFO Lucas Montarce noted that mid- to high-single-digit price erosion is expected to persist, while management stressed ongoing uncertainties related to trade policy and reimbursement dynamics. The company is focused on executing its manufacturing expansion and pipeline milestones, with the upcoming orforglipron obesity trial results cited as a key event. Lilly's management attributed the quarter's revenue growth to robust demand for diabetes and obesity therapies, new product launches, and progress in expanding global access. At the same time, profit margins were affected by increased R&D and marketing investments, as well as acquired in-process R&D charges. GLP-1 Portfolio Expansion: Uptake of Mounjaro in diabetes and Zepbound in obesity was a major growth driver, with both products gaining market share in the U.S. and international markets. Zepbound also launched higher-dose vials, aimed at improving patient access through self-pay channels. Immunology and Neuroscience Progress: Ebglyss in atopic dermatitis showed improving patient starts and coverage, with further reimbursement gains anticipated. Kisunla, for Alzheimer's disease, is approved in 12 countries, with increasing adoption but expectations for a gradual build in the market. Manufacturing Investment: The company announced plans to more than double U.S. manufacturing investments, totaling over $50 billion since 2020, including four new facilities to support future supply needs and reduce reliance on imports. Pipeline Advancements: Orforglipron's positive Phase 3 results in diabetes support its potential as an oral GLP-1 therapy, with further obesity data expected soon. Additional late-stage programs in oncology and cardiometabolic health also advanced. Tariff and Pricing Pressures: Management addressed recent U.S. trade policies and pharmacy benefit manager (PBM) decisions, noting that announced tariffs are not expected to materially affect 2025 results, but ongoing pricing and reimbursement negotiations remain a key focus. Management's outlook for the rest of the year centers on maintaining revenue momentum through new product launches and expanded access, while navigating pricing pressures and external policy risks. Pricing and Reimbursement Dynamics: Persistent mid- to high-single-digit price erosion in the U.S. and Europe, influenced by PBM formulary changes and competitive discounting, is expected to weigh on profits. Pipeline and Launch Execution: Upcoming data readouts for orforglipron in obesity, as well as continued launches in international markets for Mounjaro and Zepbound, are seen as crucial for sustaining growth. Manufacturing and Supply Expansion: The scaling of U.S. manufacturing capacity is intended to support both domestic supply and export growth, potentially mitigating risks from future trade or tariff actions. Asad Haider (Goldman Sachs): Asked about the impact of the CVS formulary decision favoring a competitor over Zepbound. CEO Dave Ricks explained that while such PBM moves are expected, Lilly aims to expand access and avoid limiting patient and physician choice. Geoff Meacham (Citibank): Inquired about the breadth of indications for orforglipron and whether its oral format could expand usage beyond current injectable therapies. Dr. Dan Skovronsky indicated confidence in pursuing broader indications, including combinations for immunology and neuroscience. Chris Schott (JPMorgan): Sought clarification on orforglipron's potential role relative to injectables in diabetes and obesity. Management highlighted that a substantial share of patients prefer oral therapies, supporting significant global opportunity. Tim Anderson (Bank of America): Questioned the prevalence of exclusive PBM arrangements in obesity drug coverage. Lilly replied that such 'one of one' formulary strategies are rare but acknowledged ongoing negotiations and market evolution. Evan Seigerman (BMO Capital Markets): Asked about the withdrawal of the heart failure indication for Tirzepatide. Dr. Skovronsky said additional trials are required by the FDA, but noted that patients in the study are already eligible under existing obesity indications. In the coming quarters, the StockStory team will be monitoring (1) the readout of orforglipron obesity trials and subsequent regulatory submissions, (2) progress in expanding U.S. and international reimbursement for key products like Zepbound and Ebglyss, and (3) the pace of manufacturing expansion and its impact on supply reliability. We will also track further data from late-stage pipeline assets and any shifts in PBM or trade policy that could influence pricing or access. Eli Lilly currently trades at a forward P/E ratio of 28.2×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
